image credit: Pexels

Dr. Reddy’s gets FDA nod for orally disintegrating lansoprazole 

February 23, 2021


Dr. Reddy’s Laboratories has introduced an orally disintegrating formulation of lansoprazole to the U.S. market. The new product is the therapeutic equivalent of the Prevacid SoluTab delayed-release tablets sold by Takeda.

Lansoprazole is a proton pump inhibitor, a mechanism of action designed to reduce the amount of acid made in the stomach and thereby treat conditions including indigestion, heartburn, acid reflux and gastroesophageal reflux disease. Researchers developed an orally disintegrating form of the active ingredient in the early 2000s as a convenient option that can be taken without water.

Read More on FiercePharma